DOCSLIB.ORG

Compositions, Methods and Devices for Generating Nanotubes on a Surface

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Compositions, Methods and Devices for Generating Nanotubes on a Surface Michigan Technological University Digital Commons @ Michigan Tech Michigan Tech Patents Vice President for Research Office 6-28-2016 Compositions, methods and devices for generating nanotubes on a surface Craig Richard Freidrich Michigan Technological University, [email protected] Tolou Shokuhfar Michigan Technological University, [email protected] Follow this and additional works at: https://digitalcommons.mtu.edu/patents Recommended Citation Freidrich, Craig Richard and Shokuhfar, Tolou, "Compositions, methods and devices for generating nanotubes on a surface" (2016). Michigan Tech Patents. 131. https://digitalcommons.mtu.edu/patents/131 Follow this and additional works at: https://digitalcommons.mtu.edu/patents US009376759B2 (12) United States Patent (io) Patent No.: US 9,376,759 B2 Friedrich et al. (45) Date of Patent: Jun. 28, 2016 (54) COMPOSITIONS, METHODS AND DEVICES (58) Field of Classification Search FOR GENERATING NANOTUBES ON A None SURFACE See application file for complete search history. (71) Applicant: MICHIGAN TECHNOLOGICAL (56) References Cited UNIVERSITY, Houghton, MI (US) U.S. PATENT DOCUMENTS (72) Inventors: Craig Richard Friedrich, Houghton, 2004/0176828 Al 9/2004 O’Brien MI (US); Tolou Shokuhfar, Houghton, 2009/0014322 A l * 1/2009 Ramarajan et al............ 204/286.1 MI (US) 2009/0093881 Al * 4/2009 Bandyopadhyay ... A61L 27/306 623/16.11 (73) Assignee: Michigan Technological University, (Continued) Houghton, MI (US) FOREIGN PATENT DOCUMENTS ( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 WO 2004/085098 10/2004 U.S.C. 154(b) by 200 days. w o 2011/116085 1/2011 w o 2013/040208 3/2013 (21) Appl.No.: 13/798,287 OTHER PUBLICATIONS (22) Filed: Mar. 13, 2013 Panaitescu, Eugen, “Titanium oxide nanotubes: synthesis, properties and applications for solar energy harvesting” (2009). Physics Disser­ (65) Prior Publication Data tations. Paper 13, pp. 1-136.* US 2013/0196128 A l Aug. 1, 2013 (Continued) Related U.S. Application Data Primary Examiner — Carlos Azpuru Assistant Examiner — Casey Hagopian (63) Continuation-in-part of application No. PCT/US2011/051578, filed on Sep. 14, 2011, and a (74) Attorney, Agent, or Firm — Michael Best & Friedrich continuation-in-part of application No. LLP PCT/US2012/055163, filed on Sep. 14, 2012. (57) ABSTRACT (60) Provisional application No. 61/382,761, filed on Sep. A method for modifying a surface by generating nanotubes at 14, 2010, provisional application No. 61/534,739, one or more selected sites on the surface, the surface includ­ filed on Sep. 14, 2011. ing a first metal. The method includes the steps of positioning at least one cathode and at least one anode relative to the (51) Int.Cl. surface in an electrolyte solution including a fluoride salt of a C2SD 7/00 (2006.01) second metal, and applying a voltage between the at least one C2SD11/02 (2006.01) anode and the at least one cathode sufficient to generate (Continued) nanotubes at one or more selected sites on the surface and to inhibit nanotube formation at one or more of the other (52) U.S. Cl. selected sites, wherein the nanotubes include the first metal CPC ................ C2SD 11/022 (2013.01); C2SD 7/00 and the second metal. (2013.01); C2SD 11/005 (2013.01); C25D 11/26 (2013.01); Y10T428/24917 (2015.01) 22 Claims, 32 Drawing Sheets US 9,376,759 B2 Page 2 (51) Int.Cl. Watcharenwong, A. et al., “Self-organized Ti02 nanotube arrays by C25D11/00 (2006.01) anodization of Ti substrate: Effect of anodization time, voltage and C25D11/26 (2006.01) medium composition on oxide morphology and photoelectrochemi- cal response” J. Mater. Res. 2007, vol. 22, No. 11, pp. 3136-3195. Zhang, H. et al., “Fabrication of Highly Ordered Ti02 Nanorod/ (56) References Cited Nanotube Adjacent Arrays for Photoelectrochemical Applications” Langmuir 2010, vol. 26, No. 13, pp. 11226-11232, Apr. 12, 2010. U.S. PATENT DOCUMENTS PCT/US2011/055163 International Search Report dated Nov. 9, 2012 (2 pages). 2009/0168139 A l* 7/2009 Hayashi et al.................. 359/269 Dunn et al. “Corrosion of Silver-Plated Copper Conductors”, ESA 2010/0024879 Al 2/2010 Richter et al. Journal, 1984 (Retrieved on Oct. 21, 2012), vol. 8, pp. 307-335, 2010/0187172 Al 7/2010 Paulose et al. <URL: http://nepp.nasa.gov>. 2011/0089041 Al 4/2011 Gupta et al. Das et al., “Estimation of Shelf Life of Natural Rubber Latex Exam- 2011/0116085 Al 5/2011 Lim et al. Gloves Based on Creep Behavior” J Biomedical Materials Research 2011/0125263 Al 5/2011 Webster et al. Part B: Applied Biomaterials 87B, May 2, 2008, pp. 398-408. 2011/0143127 Al 6/2011 Gupta et al. Inoue et al, “Antibacterial properties of nano structured silver titanate thin films formed on a titanium plate” J Biomedical Materials OTHER PUBLICATIONS Research Part A, 92A, Mar. 3, 2010, pp. 1171-1180. Thiel et al., “Antibacterial Properties of Silver-Doped Titania” Small Dunn et al. “Corrosion of Silver-Plated Copper Conductors”, ESA 3,5,2007, pp. 799-803. Journal, 1984, vol. 8, pp. 307-335.* Tao et al., “Fabrication of titania nanotube arrays on curved surface” Grimes et al. “Fabrication of Ti02 Nanotube Arrays by Electro­ Elsevier, Electrochemistry Communications 10 (2008) 1161-1163. chemical Anodization: Four Synthesis Generations”, 2009, pp. Written Opinion for Application No. PCT/US2012/055163 dated 1-66 * Nov. 9, 2012 (5 pages). PCT/US2011/051578 International Preliminary Report on Patent­ ability and Written Opinion dated Mar. 28, 2013 (8 pages). * cited by examiner U.S. Patent Jun. 28, 2016 Sheet 1 of 32 US 9,376,759 B2 Figure 1 U.S. Patent Jun. 28, 2016 Sheet 2 of 32 US 9,376,759 B2 Figure 2 U.S. Patent Jun. 28, 2016 Sheet 3 of 32 US 9,376,759 B2 Figure 3 U.S. Patent Jun. 28, 2016 Sheet 4 of 32 US 9,376,759 B2 Figure 4A Figure 4B U.S. Patent Jun. 28, 2016 Sheet 5 of 32 US 9,376,759 B2 Figure 5A Figure 5B U.S. Patent Jun. 28, 2016 Sheet 6 of 32 US 9,376,759 B2 High Resolution Electron TEM image show s diffraction pattern no sign of show s a fuzzy ring crystalline order Bright field TEM image of Ti02 nano tube Figure 6A High Resolution Electron TEM image shows diffraction shows crystalline order spot pattern of anatase phase Bright field TEM image of TiO2 nanotube Figure 6B U.S. Patent Jun. 28, 2016 Sheet 7 of 32 US 9,376,759 B2 Figure 7A Figure 7B U.S. Patent Jun. 28, 2016 Sheet 8 of 32 US 9,376,759 B2 Figure 8 U.S. Patent Jun. 28, 2016 Sheet 9 of 32 US 9,376,759 B2 Figure 9A Figure 9B U.S. Patent Jun. 28, 2016 Sheet 10 of 32 US 9,376,759 B2 Figure 10 U.S. Patent Jun. 28, 2016 Sheet 11 of 32 US 9,376,759 B2 Figure 11 U.S. Patent Jun. 28, 2016 Sheet 12 of 32 US 9,376,759 B2 Figure 12 U.S. Patent Jun. 28, 2016 Sheet 13 of 32 US 9,376,759 B2 Figure 13 U.S. Patent Jun. 28, 2016 Sheet 14 of 32 US 9,376,759 B2 Figure 14 U.S. Patent Jun. 28, 2016 Sheet 15 of 32 US 9,376,759 B2 Figure 15 U.S. Patent Jun. 28, 2016 Sheet 16 of 32 US 9,376,759 B2 Figure 16 U.S. Patent Jun. 28, 2016 Sheet 17 of 32 US 9,376,759 B2 Figure 17 U.S. Patent Jun. 28, 2016 Sheet 18 of 32 US 9,376,759 B2 Figure 18 U.S. Patent Jun. 28, 2016 Sheet 19 of 32 US 9,376,759 B2 Figure 19 U.S. Patent Jun. 28, 2016 Sheet 20 of 32 US 9,376,759 B2 Figure 20 U.S. Patent Jun. 28, 2016 Sheet 21 of 32 US 9,376,759 B2 Figure 21 U.S. Patent Jun. 28, 2016 Sheet 22 of 32 US 9,376,759 B2 Figure 22 U.S. Patent Jun. 28, 2016 Sheet 23 of 32 US 9,376,759 B2 Figure 23 U.S. Patent Jun. 28, 2016 Sheet 24 of 32 US 9,376,759 B2 Figure 24A Figure 24B U.S. Patent Jun. 28, 2016 Sheet 25 of 32 US 9,376,759 B2 Figure 25 U.S. Patent Jun. 28, 2016 Sheet 26 of 32 US 9,376,759 B2 Figure 26 U.S. Patent Jun. 28, 2016 Sheet 27 of 32 US 9,376,759 B2 Figure 27 U.S. Patent Jun. 28, 2016 Sheet 28 of 32 US 9,376,759 B2 Figure 28 U.S. Patent Jun.28, 2016 Sheet 29 of 32 US 9,376,759 B2 Figure IS U.S. Patent Jun. 28, 2016 Sheet 30 of 32 US 9,376,759 B2 Figure 30B U.S. Patent Jun. 28, 2016 Sheet 31 of 32 US 9,376,759 B2 Figure 31 U.S. Patent Jun. 28, 2016 Sheet 32 of 32 US 9,376,759 B2 Figure 32 US 9,376,759 B2 1 2 COMPOSITIONS, METHODS AND DEVICES defined by the invention were isolated or otherwise manufac­ FOR GENERATING NANOTUBES ON A tured in connection with the examples provided below. Other SURFACE features and advantages of the invention will be apparent from the detailed description, and from the claims. CROSS-REFERENCE TO RELATED 5 In one embodiment the invention provides a method for APPLICATIONS modifying a surface by generating nanotubes at one or more selected sites on the surface, the surface including a first This application is a continuation-in-part of PCT/US2011/ metal.
Load more

Recommended publications
  • Trihydroxyisoflavone Improves Skin Barrier Function Impaired by E
    www.nature.com/scientificreports OPEN A novel mineralocorticoid receptor antagonist, 7,3’,4’‑trihydroxyisofavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids Hanil Lee1,5, Eun‑Jeong Choi2,5, Eun Jung Kim1, Eui Dong Son2, Hyoung‑June Kim2, Won‑Seok Park2, Young‑Gyu Kang2, Kyong‑Oh Shin3, Kyungho Park3, Jin‑Chul Kim4, Su‑Nam Kim4 & Eung Ho Choi1* Excess glucocorticoids (GCs) with either endogenous or exogenous origins deteriorate skin barrier function. GCs bind to mineralocorticoid and GC receptors (MRs and GRs) in normal human epidermal keratinocytes (NHEKs). Inappropriate MR activation by GCs mediates various GC‑induced cutaneous adverse events. We examined whether MR antagonists can ameliorate GC‑mediated skin barrier dysfunction in NHEKs, reconstructed human epidermis (RHE), and subjects under psychological stress (PS). In a preliminary clinical investigation, topical MR antagonists improved skin barrier function in topical GC‑treated subjects. In NHEKs, cortisol induced nuclear translocation of GR and MR, and GR and MR antagonists inhibited cortisol‑induced reductions of keratinocyte diferentiation. We identifed 7,3’,4’‑trihydroxyisofavone (7,3’,4’‑THIF) as a novel compound that inhibits MR transcriptional activity by screening 30 cosmetic compounds. 7,3’,4’‑THIF ameliorated the cortisol efect which decreases keratinocyte diferentiation in NHEKs and RHE. In a clinical study on PS subjects, 7,3’,4’‑ THIF (0.1%)‑containing cream improved skin barrier function, including skin surface pH, barrier recovery rate, and stratum corneum lipids. In conclusion, skin barrier dysfunction owing to excess GC is mediated by MR and GR; thus, it could be prevented by treatment with MR antagonists. Therefore, topical MR antagonists are a promising therapeutic option for skin barrier dysfunction after topical GC treatment or PS.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Formulary Updates Effective January 1, 2021
    Formulary Updates Effective January 1, 2021 Dear Valued Client, Please see the following lists of formulary updates that will apply to the HometownRx Formulary effective January 1 st , 2021. As the competition among clinically similar products increases, our formulary strategy enables us to prefer safe, proven medication alternatives and lower costs without negatively impacting member choice or access. Please note: Not all drugs listed may be covered under your prescription drug benefit. Certain drugs may have specific restrictions or special copay requirements depending on your plan. The formulary alternatives listed are examples of selected alternatives that are on the formulary. Other alternatives may be available. Members on a medication that will no longer be covered may want to talk to their healthcare providers about other options. Medications that do not have alternatives will be available at 100% member coinsurance . Preferred to Non -Preferred Tier Drug Disease State /Drug Class Preferred Alternatives ALREX Eye inflammation loteprednol (generic for LOTEMAX) APRISO 1 Gastrointestinal agent mesalamine (generic for APRISO) BEPREVE Eye allergies azelastine (generic for OPTIVAR) CIPRODEX 1 Ear inflammation ciprofloxacin-dexamethasone (generic for CIPRODEX) COLCRYS 1 Gout colchicine (generic for COLCRYS) FIRST -LANSOPRAZOLE Gastrointestinal agent Over-the-counter lansoprazole without a prescription FIRST -MOUTHWASH BLM Mouth inflammation lidocaine 2% viscous solution (XYLOCAINE) LOTEMAX 1 Eye inflammation loteprednol etabonate (generic
    [Show full text]
  • Breeding Laboratories (Hino, Japan)
    VOL. XLII NO. 6 THE JOURNAL OF ANTIBIOTICS 989 STIMULATORY EFFECT OF CEFODIZIME ON MACROPHAGE- MEDIATED PHAGOCYTOSIS Kazunori Oishi, Keizo Matsumoto, Masashi Yamamoto, Toshihiro Morito and Toshiaki Yoshida Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, 12-4 Sakamoto-machi, Nagasaki 852, Japan (Received for publication January 27, 1989) Weevaluated the ingestion of anti-sheep erythrocyte (anti-E) IgG- and IgM-coated sheep erythiocytes by murineperitoneal macrophagesexposed to cefodizime, a newsemisynthetic cephalosporin, and other antibiotics. Cefodizime enhanced the ingestion of anti-E IgG- coated erythrocytes by peritoneal macrophages from CD-I and BALB/cmice in a dose- dependent manner, but had no effect on uncoated or IgM-coated erythrocytes. Similar enhancement was observed only in the case of cefpimizole (AC-1370), among the other anti- biotics examined. These results suggest that the favorable in vivo activity of cefodizime and cefpimizole may result from their phagocytosis-enhancing as well as antimicrobial properties. The new semisynthetic cephalosporin, cefodizime, is characterized by a cephem ring which con- tains a ^w-methoxyimino-aminothiazolyl group at the 7-position and a thiazolylthio-methyl group at the 3-position. The latter substitution is thought to provide metabolic stability and a prolonged half-life in humanserum0. The efficacy of cefodizime in experimental murine infections is apparently superior to that predicted from in vitro activity2>3). Wepostulated that the enhanced in vivo activity of cefodizime may be due to drug-induced immunostimulation. This speculation was in part based upon the previous demonstration that a variety of agents, including lysophosphatidylcholine4) and fibronectin5), enhance receptor-dependent phagocytosis. Moreover, it was previously reported that cefpimizole (AC-1370), another semisynthetic cephalosporin, potentiated phagocyte function of macrophages and neutrophils6).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • 1532 Corticosteroids
    1532 Corticosteroids olone; Ultraderm; Malaysia: Synalar†; Mex.: Cortifung-S; Cortilona; Gr.: Lidex; Ital.: Flu-21†; Topsyn; Mex.: Topsyn; Norw.: Metosyn; Pharmacopoeias. In Br. Cremisona; Farmacorti; Flumicin; Fluomex; Fusalar; Lonason; Synalar; Philipp.: Lidemol; Lidex; Singapore: Lidex†; Spain: Klariderm†; Novoter; BP 2008 (Fluocortolone Hexanoate). A white or creamy-white, Norw.: Synalar; NZ: Synalar; Philipp.: Aplosyn; Cynozet; Synalar; Syntop- Switz.: To p s y m ; To p s y m i n ; UK: Metosyn; USA: Lidex; Vanos. ic; Pol.: Flucinar; Port.: Oto-Synalar N; Synalar; Rus.: Flucinar (Флуцинар); odourless or almost odourless, crystalline powder. It exhibits pol- Multi-ingredient: Austria: Topsym polyvalent; Ger.: Jelliproct; Topsym ymorphism. Practically insoluble in water and in ether; very Sinaflan (Синафлан); S.Afr.: Cortoderm; Fluoderm; Synalar; Singapore: polyvalent; Hung.: Vipsogal†; Israel: Comagis; Mex.: Topsyn-Y; Philipp.: Flunolone-V; Spain: Co Fluocin Fuerte; Cortiespec; Fluocid Forte; Fluoder- Lidex NGN; Spain: Novoter Gentamicina; Switz.: Mycolog N; Topsym slightly soluble in alcohol and in methyl alcohol; slightly soluble mo Fuerte; Flusolgen; Gelidina; Intradermo Corticosteroi†; Synalar; Synalar polyvalent; UK: Vipsogal. in acetone and in dioxan; sparingly soluble in chloroform. Pro- Rectal Simple; Swed.: Synalar; Switz.: Synalar; Thai.: Cervicum; Flu- ciderm†; Flunolone-V; Fulone; Supralan; Synalar; UK: Synalar; USA: Capex; tect from light. Derma-Smoothe/FS; DermOtic; Fluonid; Flurosyn†; Retisert; Synalar; Syn- emol; Venez.: Bratofil; Fluquinol Simple†; Neo-Synalar; Neoflu†. Fluocortin Butyl (BAN, USAN, rINNM) ⊗ Fluocortolone Pivalate (BANM, rINNM) ⊗ Multi-ingredient: Arg.: Adop-Tar†; Tri-Luma; Austria: Myco-Synalar; Procto-Synalar; Synalar N; Belg.: Procto-Synalar; Synalar Bi-Otic; Braz.: Butil éster de la fluocortina; Butylis Fluocortinas; Fluocortine Fluocortolone, pivalate de; Fluocortolone Trimethylacetate; Dermobel†; Dermoxin; Elotin; Fluo-Vaso; Neocinolon; Otauril†; Otocort†; Butyle; SH-K-203.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]